Profile data is unavailable for this security.
About the company
ZYUS Life Sciences Corporation is a Canada-based life sciences company focused on developing and commercializing cannabinoid-based pharmaceutical drug candidates for pain management. Its lead research program is focused on developing a purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its lead/first drug product candidate in this program, Trichomylin softgel capsules, is a fixed dose combination of cannabinoids formulated for the treatment of chronic pain in adults. This formulation offers oral administration of highly purified cannabinoids in a controlled dosage. In parallel with the research conducted respecting Trichomylin softgel capsules, it has also identified and commenced research on a second drug candidate. This drug candidate is a cannabinoid-based therapeutic composition for pain management. Both pre-clinical and non-clinical studies have been conducted on this formulation and patent applications have been filed.
- Revenue in CAD (TTM)465.00k
- Net income in CAD-33.74m
- Incorporated1944
- Employees2.00
- LocationZYUS Life Sciences Corp407 Downey Road, Unit 204SASKATOON S7N 4L8CanadaCAN
- Phone+1 (306) 242-2357
- Fax+1 (416) 368-4440
- Websitehttps://www.zyus.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thiogenesis Therapeutics Corp | 0.00 | -6.82m | 29.03m | -- | -- | 13.48 | -- | -- | -0.1439 | -0.1439 | 0.00 | 0.0415 | 0.00 | -- | -- | -- | -173.15 | -- | -216.52 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.87 | -- | -- | -- |
| Principal Technologies Inc | 262.84k | -4.32m | 29.19m | -- | -- | -- | -- | 111.07 | -0.1043 | -0.1072 | 0.0063 | -0.0126 | 0.2272 | -- | 1.68 | -- | -372.16 | -- | -2,615.25 | -- | -- | -- | -1,637.81 | -- | -- | -223.78 | -- | -- | -44.22 | -- | -162.24 | -- | -- | -- |
| Resverlogix Corp | 0.00 | -9.61m | 30.18m | 18.00 | -- | -- | -- | -- | -0.0339 | -0.0339 | 0.00 | -0.4198 | 0.00 | -- | -- | 0.00 | -91.25 | -- | -- | -- | -- | -- | -- | -- | 0.0248 | -1.30 | -- | -- | -- | -- | 54.39 | -- | -- | -- |
| Microbix Biosystems Inc | 18.59m | -2.25m | 31.87m | 69.00 | -- | 1.15 | -- | 1.71 | -0.0161 | -0.0161 | 0.1344 | 0.1992 | 0.4923 | 1.12 | 6.44 | -- | -5.95 | 3.86 | -6.48 | 4.37 | 53.02 | 55.92 | -12.08 | 6.37 | 5.17 | -2.23 | 0.196 | -- | -26.81 | 12.04 | -163.80 | -- | -0.4115 | -- |
| MustGrow Biologics Corp | 7.54m | -6.37m | 40.23m | 0.00 | -- | 12.95 | -- | 5.34 | -0.1206 | -0.1206 | 0.1435 | 0.0494 | 1.45 | 5.49 | 45.16 | -- | -122.84 | -54.87 | -193.93 | -66.95 | 14.51 | -- | -84.52 | -341.26 | 1.25 | -103.31 | 0.1671 | -- | -91.55 | -- | -622.18 | -- | -- | -- |
| Briacell Therapeutics Corp | 0.00 | -38.90m | 41.61m | 22.00 | -- | 0.7996 | -- | -- | -72.20 | -72.20 | 0.00 | 7.18 | 0.00 | -- | -- | 0.00 | -246.96 | -63.88 | -359.42 | -70.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -449.14 | -- | -- | -- |
| ZYUS Life Sciences Corp | 465.00k | -33.74m | 48.36m | 2.00 | -- | -- | -- | 104.01 | -0.4505 | -0.4505 | 0.0062 | -0.1659 | 0.0208 | 0.3346 | 1.17 | -- | -150.55 | -74.90 | -454.68 | -102.81 | 13.12 | 3.61 | -7,256.77 | -8,974.20 | 0.0726 | -9.28 | 6.94 | -- | 37.04 | 313.06 | 20.63 | -- | -- | -- |
| Nurexone Biologic Inc | 0.00 | -8.85m | 58.02m | 9.00 | -- | 26.72 | -- | -- | -0.1189 | -0.1189 | 0.00 | 0.0239 | 0.00 | -- | -- | -- | -208.79 | -215.30 | -263.35 | -529.63 | -- | -- | -- | -- | -- | -102.73 | 0.0514 | -- | -- | -- | -38.58 | -- | -- | -- |
| Medicenna Therapeutics Corp | 0.00 | -13.82m | 65.89m | 18.00 | -- | 6.43 | -- | -- | -0.1696 | -0.1696 | 0.00 | 0.1228 | 0.00 | -- | -- | 0.00 | -54.21 | -56.44 | -63.31 | -63.20 | -- | -- | -- | -- | -- | -- | 0.0143 | -- | -- | -- | 53.64 | -- | -- | -- |
| Sharp Therapeutics Corp | 0.00 | -9.19m | 66.01m | -- | -- | 34.40 | -- | -- | -4.11 | -4.11 | 0.00 | 0.0639 | 0.00 | -- | -- | -- | -435.86 | -- | -512.62 | -- | -- | -- | -- | -- | -- | -- | 0.477 | -- | -- | -- | -2,282.81 | -- | -- | -- |
